Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM)
Phase of Trial: Phase IV
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Pioglitazone (Primary)
- Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms UTHSCSA NASH
- 15 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 26 Apr 2012 Planned End Date changed from 1 Jul 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.